{"id":"W2009611159","doi":"10.1111/ijcp.12433","title":"Safety and tolerability of the β<sub>3</sub>‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial","year":2014,"lang":"en","type":"article","venue":"International Journal of Clinical Practice","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Allergan; Astellas Pharma; Astellas Foundation for Research on Metabolic Disorders; Pfizer; Coloplast; Ipsen; Teva Pharmaceutical Industries","keywords":"Tolerability; Mirabegron; Medicine; Overactive bladder; Placebo; Tolterodine; Adverse effect; Urology; Internal medicine; Anesthesia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01135362,0.001130452,0.003466367,0.0006416729,0.0002562321,0.001588227,0.0006544321,0.001179487,0.001607798],"category_scores_gemma":[0.007185857,0.0006731434,0.006961864,0.000732762,0.0006299441,0.000818658,0.0005228549,0.001260602,0.0002220257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005153477,"about_ca_system_score_gemma":0.0006981316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003420443,"about_ca_topic_score_gemma":0.000912339,"domain_scores_codex":[0.9955165,0.002944318,0.0005860169,0.0003812892,0.0004569341,0.0001150087],"domain_scores_gemma":[0.9932992,0.002566767,0.003106561,0.0003840713,0.0003527719,0.0002905037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7650078,0.001353171,0.01984433,0.0143741,0.1282891,0.0001219362,0.0001728475,0.001400247,0.008538759,0.00008856971,0.0009617539,0.0598474],"study_design_scores_gemma":[0.4854855,0.1407651,0.1509257,0.001595541,0.2097805,0.0006383311,0.0002057084,0.001832474,0.004495887,0.0004165295,0.003678881,0.0001799301],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8177411,0.1757378,0.001741313,0.0005789167,0.0003085804,0.001152166,0.001412961,0.00008849497,0.001238692],"genre_scores_gemma":[0.9757117,0.02070389,0.001109197,0.0004327429,0.000270218,0.0004951326,0.0009239005,0.00002368172,0.0003296433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01135362,"threshold_uncertainty_score":0.06004435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08926726579271346,"score_gpt":0.4568707791945406,"score_spread":0.3676035134018271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}